NASDAQ:VERU Veru Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Veru Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.63 -0.04 (-1.50 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$2.57Now: $2.63▼$2.6850-Day Range$2.62MA: $2.80▼$3.1952-Week Range$1.85Now: $2.63▼$4.74Volume365,680 shsAverage Volume548,954 shsMarket Capitalization$183.74 millionP/E RatioN/ADividend YieldN/ABeta0.14 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingVeru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Veru has a forecasted upside of 185.2% from its current price of $2.63.Amount of Analyst CoverageVeru has only been the subject of 2 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesVeru has received 235 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVeru has received 171 “underperform” votes. (Add your “underperform” vote.)Community SentimentVeru has received 57.88% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote “Outperform” if you believe VERU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVeru does not currently pay a dividend.Dividend GrowthVeru does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veru insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,050.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 26.10% of the stock of Veru is held by insiders.Percentage Held by InstitutionsOnly 23.13% of the stock of Veru is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Veru are expected to decrease in the coming year, from ($0.16) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veru is -16.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veru is -16.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeru has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.88 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPersonal Products SectorMedical Current SymbolNASDAQ:VERU Previous Symbol CUSIP31446210 CIK863894 Webwww.veruhealthcare.com Phone305-509-6897Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.80 million Price / Sales5.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book5.26Profitability EPS (Most Recent Fiscal Year)($0.19) Net Income$-12,020,000.00 Net Margins-25.78% Return on Equity-30.37% Return on Assets-17.80%Miscellaneous Employees171 Outstanding Shares69,864,000Market Cap$183.74 million Next Earnings Date12/10/2020 (Estimated) OptionableOptionable $2.63 -0.04 (-1.50 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VERU News and Ratings via Email Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter. Veru (NASDAQ:VERU) Frequently Asked Questions How has Veru's stock price been impacted by Coronavirus? Veru's stock was trading at $3.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VERU shares have decreased by 17.8% and is now trading at $2.63. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Veru? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veru. When is Veru's next earnings date? Veru is scheduled to release its next quarterly earnings announcement on Thursday, December 10th 2020. View our earnings forecast for Veru. How were Veru's earnings last quarter? Veru Inc (NASDAQ:VERU) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.02. The firm earned $10.32 million during the quarter, compared to analysts' expectations of $10.68 million. Veru had a negative net margin of 25.78% and a negative return on equity of 30.37%. View Veru's earnings history. What price target have analysts set for VERU? 3 brokers have issued 1 year price objectives for Veru's stock. Their forecasts range from $6.00 to $9.00. On average, they expect Veru's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 185.2% from the stock's current price. View analysts' price targets for Veru. Are investors shorting Veru? Veru saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,000,000 shares, an increase of 24.2% from the August 15th total of 1,610,000 shares. Based on an average daily volume of 817,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 3.7% of the shares of the company are short sold. View Veru's Short Interest. Who are some of Veru's key competitors? Some companies that are related to Veru include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Medifast (MED), Prestige Consumer Healthcare (PBH), USANA Health Sciences (USNA), Inter Parfums (IPAR), Revlon (REV) and Nature's Sunshine Products (NATR). View all competitors. What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Corbus Pharmaceuticals (CRBP), Kadmon (KDMN), Matinas BioPharma (MTNB), OrganiGram (OGI), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Vaxart (VXRT), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO) and VBI Vaccines (VBIV). Who are Veru's key executives? Veru's management team includes the following people: Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)Mr. O. B. Parrish, Co-Founder & Director (Age 86)Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51) What is Veru's stock symbol? Veru trades on the NASDAQ under the ticker symbol "VERU." Who are Veru's major shareholders? Veru's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (0.59%), Wedge Capital Management L L P NC (0.43%), Nuveen Asset Management LLC (0.34%), EAM Investors LLC (0.23%), Two Sigma Advisers LP (0.19%) and Bank of New York Mellon Corp (0.20%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View institutional ownership trends for Veru. Which institutional investors are selling Veru stock? VERU stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., EAM Investors LLC, AWM Investment Company Inc., Bank of America Corp DE, Wedge Capital Management L L P NC, and Engineers Gate Manager LP. View insider buying and selling activity for Veru. Which institutional investors are buying Veru stock? VERU stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Two Sigma Advisers LP, New York State Common Retirement Fund, American International Group Inc., SG Americas Securities LLC, and HighTower Advisors LLC. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Jesus Socorro, K Gary Barnette, and Michele Greco. View insider buying and selling activity for Veru. How do I buy shares of Veru? Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Veru's stock price today? One share of VERU stock can currently be purchased for approximately $2.63. How big of a company is Veru? Veru has a market capitalization of $183.74 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe. What is Veru's official website? The official website for Veru is www.veruhealthcare.com. How can I contact Veru? Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
